Clinical Trials Logo

Filter by:
NCT ID: NCT03276585 Enrolling by invitation - Depression Clinical Trials

Night in Japan Home Sleep Monitoring Study

NinJaSleep
Start date: September 6, 2017
Phase:
Study type: Observational

The investigators hypothesized that depression is associated with home sleep EEG, subjective sleepiness and insomnia symptoms. To test this, the investigators plan to perform sleep examination with single channel EEG, in combination with questionnaire survey for insomnia, sleepiness, depression and job stress to Koka city government employees.

NCT ID: NCT03275402 Terminated - Neuroblastoma Clinical Trials

131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Start date: December 11, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Children with a neuroblastoma diagnose and central nervous system (CNS)/leptomeningeal metastases will be given up to 2 rounds of intracerebroventricular treatment with a radiolabelled monoclonal antibody, 131I-omburtamab to evaluate efficacy and safety

NCT ID: NCT03275285 Active, not recruiting - Plasma Cell Myeloma Clinical Trials

Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients

IKEMA
Start date: October 25, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study it to compare the efficacity of isatuximab when combined to carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with multiple myeloma already treated with 1 to 3 prior lines of therapy.

NCT ID: NCT03274492 Active, not recruiting - Clinical trials for Diffuse Large B-Cell Lymphoma

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

POLARIX
Start date: November 16, 2017
Phase: Phase 3
Study type: Interventional

This Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plus R-CHP versus R-CHOP in participants with previously untreated diffuse large B-cell lymphoma (DLBCL).

NCT ID: NCT03273790 Completed - Clinical trials for Non-Small Cell Lung Cancer

A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan

Start date: April 1, 2017
Phase:
Study type: Observational

A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan

NCT ID: NCT03272945 Completed - Colonic Polyp Clinical Trials

Linked-color Imaging for the Detection of Colorectal Flat Lesions

Start date: September 6, 2017
Phase: N/A
Study type: Interventional

Linked color imaging (LCI) was recently developed and uses a laser endoscopic system (Fujifilm Co, Tokyo, Japan) that acquires images by simultaneously using narrow-band short-wavelength light and white-light (WL) in an appropriate balance. LCI is a new image-enhancing technology that is intended to enhance slight color differences in the red region of the mucosa. The acquired color information is reallocated to differentiate colors that are similar to the mucosal color, resulting in improved performance in depicting blood vessels, and additional image processing that enhances color separation for red color permits clear visualization of red blood vessels and white pits. This modality may increase the detection rate of colorectal polyps by enhancing the visibility of colonic mucosal vessels. In addition, it has been reported that LCI increases the visibility of colorectal flat lesions and contributes to improvement of the detection rate for these lesions. The primary aim of the current study was to compare the detection rate of colorectal flat lesions of LCI cap-assisted colonoscopy with WL cap-assisted colonoscopy in prospective randomized trial. In addition, we prospectively compared LCI and WL with regard to the visibility of colorectal flat lesions found in this study.

NCT ID: NCT03268954 Active, not recruiting - Clinical trials for Myelodysplastic Syndrome

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

PANTHER
Start date: November 28, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves event-free survival (EFS) when compared with single-agent azacitidine. (An event is defined as death or transformation to AML in participants with MDS or CMML, whichever occurs first, and is defined as death in participants with low-blast AML).

NCT ID: NCT03268811 Completed - Clinical trials for Short Bowel Syndrome

A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302

Start date: August 23, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this clinical study is to evaluate the long-term safety and tolerability of teduglutide treatment in Japanese pediatric participants with short bowel syndrome (SBS) who completed Study SHP633-302 (NCT02980666).

NCT ID: NCT03267303 Completed - Narcolepsy Clinical Trials

A Study to Evaluate the Safety and Efficacy of TS-091 in Patients With Narcolepsy

Start date: October 31, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety after administration of TS-091 compared with placebo in patients with narcolepsy.

NCT ID: NCT03264547 Recruiting - Breast Cancer Clinical Trials

A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

Start date: August 28, 2017
Phase: Phase 3
Study type: Interventional

To verify that combination therapy with trastuzumab + pertuzumab + eribulin brings similar PFS and better QOL compared to trastuzumab + pertuzumab + taxane in advanced/recurrent HER2-positive breast cancer patients who have no medical history of chemotherapy except ado-trastuzumab emtansine